| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President & CEO
2 companies
Brian Concannon last filed a Form 4 in June 2025, as President & CEO at HAE. The filings on record cover 2 companies.
Our model assigns Brian Concannon a strong insider score of 70/100, based on 3 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +36.1%.
At the last filing, the largest reported position was 147,040 shares of HAE. The HAE filings lean toward selling, a net 69,161 shares.
Brian Concannon has 28 Form 4 filings on record from January 2015 to June 2025, across 2 companies: Director at Conmed (CNMD), 2015–2025; President & CEO at Haemonetics (HAE), 2015.
The 75 reported transactions were 30 option exercises, 22 open-market sales, 20 option or other derivative awards and 3 tax withholdings.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $5.2M.
The largest open-market sale was 12,984 shares of CNMD at an average $135.73 on February 2, 2022, about $1.8M. Twelve months later CNMD was down 22%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2023 | CNMD Conmed Corp | Director | Sell | 812 | $129.01 | $104,756.12 | -8.0% | -16.2% | -39.9% | |
| May 1, 2023 | CNMD Conmed Corp | Director | Sell | 2,072 | $125.00 | $259,000.00 | -17.4% | -3.8% | -46.0% | |
| Feb 2, 2022 | CNMD Conmed Corp | Director | Sale+OE | 12,984 | $135.73 | $1,762,324.13 | -59.1% | -3.2% | -22.2% | |
| Sep 10, 2020 | CNMD Conmed Corp | Director | Sell | 3,036 | $89.31 | $271,145.16 | -17.9% | - | - | |
| Sep 15, 2015 | HAE Haemonetics Corp | President & CEO | Sale+OE | 6,569 | $35.15 | $230,900.35 | -4.3% | - | - | |
| Sep 1, 2015 | HAE Haemonetics Corp | President & CEO | Sale+OE | 4,765 | $35.63 | $169,792.20 | -3.1% | - | - | |
| Aug 17, 2015 | HAE Haemonetics Corp | President & CEO | Sale+OE | 6,569 | $39.28 | $258,019.15 | -4.3% | - | - | |
| Aug 3, 2015 | HAE Haemonetics Corp | President & CEO | Sale+OE | 4,765 | $39.91 | $190,189.26 | -3.1% | - | - | |
| Jul 15, 2015 | HAE Haemonetics Corp | President & CEO | Sale+OE | 6,569 | $39.59 | $260,091.67 | -4.3% | - | - | |
| Jul 1, 2015 | HAE Haemonetics Corp | President & CEO | Sale+OE | 4,765 | $41.28 | $196,711.11 | -3.1% | - | - |